Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0786
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2620
    -0.0003 (-0.02%)
     
  • USD/JPY

    151.3400
    -0.0320 (-0.02%)
     
  • Bitcoin USD

    69,886.52
    -601.38 (-0.85%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic Competition

Teva Pharmaceutical (NASDAQ: TEVA) on Thursday released its 2015 outlook.

Here are some of the business-related highlights:

  • Foreign exchange rates are expected to have a $700 million adverse impact on revenues.

  • Copaxone 20 mg/mL is expected to face two AB-rated generic competitors in the U.S. beginning in September.

  • Copaxone 40 mg/mL will be launched in the European Union and elsewhere in the first quarter.

  • Generic Pulmicort will see additional generic competition in the first of the year, resulting in a decrease of revenues by $400 to $500 million, and a decrease in operating profit of $100 to $200 million from 2014 levels.

Here are some of the financial-related highlights:

  • Net revenue of $19.0 to $19.4 billion.

  • Operating Income of $5.7 to $5.9 billion.

  • Earnings per share of $5.00 to $5.30.

  • Cash flow from operations of $4.3 billion to $4.7 billion.

  • Free cash flow of $3.5 billion to $3.7 billion.

  • Company will spend $1 billion to $1.2 billion share buybacks.

A conference call and webcast was hosted by the company on Thursday at 8:00 a.m. A replay of the webcast will available within 24 hours on the company's website.

See more from Benzinga

© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement